Market Outlook

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (coronary artery disease, stroke, and heart failure), renal failure, and death. The various guidelines available recommend to initiate drug treatment when BP is higher than target levels. The overarching goal for antihypertensive therapies is to reduce the risk of the various end organ morbidities and mortality associated with elevated BP. Hypertension is treated with a vast array of drugs belonging to a large number of classes, including numerous fixed-dose combination (FDC) products. Standard first-line treatment can involve monotherapy or combination therapy, and guidelines emphasize the additive effects of using two or more drugs from different antihypertensive drug classes. The Hypertension Treatment Algorithm provides insights into drug class prescribing patterns among a wealth of treatment options, where, owing to the high availability of generics, pricing pressures are of minimal concern.

Questions Answered

  • What patient share do key drug classes garner by line of therapy in newly diagnosed hypertensive patients?
  • What are the quarterly trends in prescribing among recentlytreated and new diagnosed hypertensive patients?
  • How have FDCs been integrated into the treatment algorithm?
  • What percentage of hypertensive patients receive drug therapy within one year of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of hypertensive patients are treated with monotherapy versus combination therapy?
  • What are the most widely used combination therapies?
  • What are the drug-class-level compliance and persistency rates among drug-treated patients with hypertension?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Key Drug Classes Covered

ACE inhibitors, ARBs, diuretics, calcium-channel blockers, beta blockers, aldosterone antagonists, and direct renin inhibitors.

Key Analysis Provided

  • Brand usage across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flow charts.

Related Reports

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (EU5)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of dr...

View Details

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Pulmonary Hypertension | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension pat...

View Details